Gammaherpesviruses establish persistent, systemic infections and cause cancers. Murid herpesvirus 4 (MuHV-4) provides a unique window into the early events of host colonization. It spreads via lymph nodes. While dendritic cells (DC) pass MuHV-4 to lymph node B cells, subcapsular sinus macrophages (SSM), which capture virions from the afferent lymph, restrict its spread. Understanding how this restriction works offers potential clues to a more comprehensive defense. Type I interferon (IFN-I) blocked SSM lytic infection and reduced lytic cycle-independent viral reporter gene expression. Plasmacytoid DC were not required, but neither were SSM the only source of IFN-I, as IFN-I blockade increased infection in both intact and SSM-depleted mice. NK cells restricted lytic SSM infection independently of IFN-I, and SSM-derived virions spread to the spleen only when both IFN-I responses and NK cells were lacking. Thus, multiple innate defenses allowed SSM to adsorb virions from the afferent lymph with relative impunity. Enhancing IFN-I and NK cell recruitment could potentially also restrict DC infection and thus improve infection control.
IMPORTANCE
Human gammaherpesviruses cause cancers by infecting B cells. However, vaccines designed to block virus binding to B cells have not stopped infection. Using a related gammaherpesvirus of mice, we have shown that B cells are infected not via cell-free virus but via infected myeloid cells. This suggests a different strategy to stop B cell infection: stop virus production by myeloid cells. Not all myeloid infection is productive. We show that subcapsular sinus macrophages, which do not pass infection to B cells, restrict gammaherpesvirus production by recruiting type I interferons and natural killer cells. Therefore, a vaccine that speeds the recruitment of these defenses might stop B cell infection.E pstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) persist in B cells and cause cancers (1). Reducing their B cell infections is therefore an important therapeutic goal. Limited viral gene expression (2) makes established infections difficult to clear. The early events of host colonization may provide better targets. However, control mechanisms must be defined in vivo: inferring mechanisms from in vitro studies has proven problematic because immune function and its evasion are context dependent. Thus, EBV gp350-specific antibodies block B cell infection, and CD8 ϩ T cells kill infected B cells in vitro, but vaccinations to induce these effectors have not reduced infection rates (3).The early events of human infections are difficult to analyze because they predate clinical presentation (4). However, gammaherpesviruses long predate human speciation (5), and peak viral diversity in genes that interact with host-diverse functions suggests that viral coevolution has since acted to counter host divergence. Therefore, human and other mammalian gammaherpesviruses should colonize their hosts in similar ways. Murid herpesvirus 4 (MuHV-4) realistically infects la...